Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 0

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 0
---
Filed Pursuant to Rule 424(b)(3)

Registration No. 333-284350

PROSPECTUS

<div align='center'>341,352,000,000 Ordinary Shares Representing 34,135,200 American Depositary Shares

___________________</div>

This prospectus relates to the potential offer and sale from time to
time by C/M Capital Master Fund, LP, or the Selling Shareholder, of up to 341,352,000,000 of our ordinary shares, nominal value £0.00005 per share, or Ordinary Shares, represented by 34,135,200 American Depositary Shares, or Depositary
Shares, that have been or may be issued by us to the Selling Shareholder pursuant to a Securities Purchase Agreement, dated as of January
17, 2025, by and between us and C/M, or the Purchase Agreement, establishing an equity line of credit, or the Equity Financing. Such Depositary
Shares include (a) 33,413,549 Depositary Shares, or the Purchase Shares, underlying 334,135,490,000 Ordinary Shares by that we may elect,
in our sole discretion, to issue and sell to the Selling Shareholder, from time to time from and after the Commencement Date (as defined
herein) under the Purchase Agreement, and subject to applicable stock exchange rules (assuming the shares to be issued and sold at a price
of $1.00 per share) and (b) up to 721,651 Depositary Shares, or the Commitment Shares, underlying 7,216,510,000 Ordinary Shares that may
be issued to the Selling Shareholder to release the Company of its liability to pay the Commitment Fee (as defined herein) as consideration
for it entering into the Purchase Agreement (assuming the shares to be issued at a price of $1.00 per share).

The actual number of shares
issuable will vary depending on the then-current market price of our Depositary Shares sold to the Selling Shareholder under the Purchase
Agreement, but will not exceed the number set forth in the preceding sentences unless we file an additional registration statement under
the Securities Act of 1933, as amended, or the Securities Act, with the Securities and Exchange Commission, or SEC. See “The Committed Equity Financing” for a description of the Purchase Agreement and “Selling Shareholder” for additional
information regarding the Selling Shareholder.

We are not selling any securities under this prospectus